Zobrazeno 81 - 90
of 15 956
pro vyhledávání: ''
Autor:
Caterina Musolino, Chiara Camerini, Emanuela Sant’Antonio, Vincenzo Rizzo, Alessandro Allegra
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:573-579
Chronic myeloid leukemia (CML) has long been considered as a model of cancer caused by a single-driver genetic lesion (BCR/ABL1 rearrangement) that codes for a unique, gain-of-function, deregulated protein. However, in the last decade, high-throughpu
Autor:
Ángela Ibañez-García, Alberto Marín-Sánchez, Irene Gómez-Catalán, Mari Carmen Montoya-Morcillo, Francisco Hernández-Fernández, Gonzalo Martínez-Fernández, Jesús Lorenzo Algarra-Algarra, Juan Ramón Romero-Macías
Publikováno v:
Experimental Hematology. :49-57
The hyper-CVAD/methotrexate-cytarabine (H-CVAD/ MTX-AraC) chemotherapy protocol has been one of the standard treatments for hematological malignancies, such as mantle cell lymphoma (MCL), Burkitt lymphoma (BL), and B-cell and T-cell acute lymphoblast
Publikováno v:
Hematology/Oncology and Stem Cell Therapy, Vol 14, Iss 3, Pp 252-256 (2021)
Primary myelofibrosis (PMF) is a subtype of BCR-ABL1 negative myeloproliferative neoplasm. Its characteristic features include clonal myeloproliferation, dysregulation of kinase signaling pathway, abnormal release of cytokines leading to fibrosis in
Autor:
Eunice S. Wang, Nicholas J. Short, Guido Marcucci, Amir T. Fathi, Hagop M. Kantarjian, Andrew H. Wei, Martin S. Tallman, Farhad Ravandi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:580-597
With the Food and Drug Administration approval of 9 agents for different acute myeloid leukemia (AML) indications, the prognosis and management of AML is evolving rapidly. Herein, we review the important milestones in the history of AML research and
Autor:
Tara Cronin, Kristopher Attwood, Eunice S. Wang, Sarah Sadek, Mark G. Faber, Swapna Thota, James E. Thompson, Jeffrey Baron, Ellen Madarang, Elizabeth A. Griffiths, Justin M. Watts, Terrence Bradley, Amanda Przespolewski, Abhay Singh
Publikováno v:
Clin Lymphoma Myeloma Leuk
The optimal approach to combine gemtuzumab-ozogamicin (GO) with various chemotherapy backbones and other newer agents safely remains to be determined. We performed a retrospective analysis of the safety and outcomes of newly diagnosed adult AML patie
Autor:
Jonathan Sussman, Tanya M. Wildes, Hira S. Mian, Mohammed S. Ebraheem, Amaris K. Balitsky, Branavan Sivapathasundaram, Gregory R. Pond, Hsien Seow
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e714-e721
Background Autologous stem cell transplant (ASCT) is an established treatment for patients with newly diagnosed multiple myeloma (NDMM). Understanding the symptom burden associated with ASCT may be an important consideration for patients with NDMM wh
Autor:
Masashi Mizumoto, Masahide Matsuda, Toshiyuki Okumura, Haruko Numajiri, Eiichi Ishikawa, Yoshiko Oshiro, Hidehiro Kohzuki, Hideyuki Sakurai, Keiichi Tanaka, Akira Matsumura, Hsiang-Kuang Tony Liang
Publikováno v:
Journal of Cancer Research and Clinical Oncology
BackgroundGlioblastoma peritumoral edema (PE) extent is associated with survival and progression pattern after tumor resection and radiotherapy (RT). To increase tumor control, proton beam was adopted to give high-dose boost (> 90 Gy). However, the c
Autor:
Mario Nuvolone, Pierluigi Russo, Giampaolo Merlini, Paolo Milani, Giovanni Affronti, Giovanni Palladini, Andrea Foli, Valentina Summa, Pier Paolo Olimpieri, Simone Celant, Sandra Petraglia
Publikováno v:
Leukemia & Lymphoma. 63:205-211
Until recently, no drug was labeled for AL amyloidosis. In 2011, the Italian Medicines Agency started a program to grant access to upfront bortezomib to patients with AL amyloidosis. All subjects were enrolled in a prospective online registry. Respon
Autor:
Giulia Debbia, Nicolò Mesini, Davide Rossi, Monica Maccaferri, Rossana Maffei, Stefania Fiorcari, Claudio Giacinto Atene, Leonardo Potenza, Silvia Martinelli, Roberto Marasca, Mario Luppi, Stefania Benatti, Gianluca Gaidano, Patrizia Zucchini, Livio Trentin, Francesca Bacchelli, Daniele Vallisa
Publikováno v:
Hematological Oncology. 39:707-711
Autor:
Sung-Won Kim, Takahiro Fukuda, Jun Aoki, Masatomo Kuno, Yoshihiro Inamoto, Tsuneaki Hirakawa, Takashi Tanaka, Ayumu Ito, Suguru Fukuhara, Koji Izutsu, Wataru Takeda, Akiko Miyagi Maeshima, Hanae Ida
Publikováno v:
Hematological Oncology. 39:650-657
This study characterized the outcomes of patients who underwent hematopoietic cell transplantation (HCT) for transformed follicular lymphoma (tFL), and clarified the association of low-dose anti-thymocyte globulin use with outcomes after allogeneic H